Armata Pharmaceuticals Inc (NYSEAMERICAN:ARMP) shares jumped after a case study of a cystic fibrosis patient successfully treated for an infection with its signature drug appeared in a peer-reviewed medical journal.
The company’s AP-PA01 treatment was used to combat a multidrug-resistant infection caused by bacteria called Pseudomonas aeruginosa.
It's stock jumped nearly 32% to close at $4.15.
The paper, "Successful adjunctive use of bacteriophage therapy for treatment of multidrug‑resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient," appears in the journal "Infection".
AP-PA01 is a bacteriophage, essentially a virus that attacks a bacterium by infecting and reproducing inside it. The California company is building on the treatment’s success by engineering a synthetic phage known as AP-PA02.
"The publication of this successful treatment case study, with an Armata phage administered through our single-patient expanded access program, adds to the impressive and growing body of evidence demonstrating the effectiveness of our phage product candidates, and bacteriophage in general," CEO Todd Patrick said. "To solidify our position as a leader in the development of phage-based therapeutics, we are currently working with key opinion leaders to map out an efficient clinical strategy for both our Pseudomonas and Staphylococcus phage product candidates.”
The clinical-stage biotechnology company plans to file an investigational new drug application for its Staphylococcus phage candidate with the Food and Drug Administration later this year.
Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com
Follow him on Twitter @andrew_kessel